BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, has announced that positive Phase 1 clinical data for BIND-014, the company’s lead drug candidate, were presented in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting…
Read More...Cancer News
- Bladder Cancer (65)
- Brain Tumor Cancer (38)
- Breast Cancer (8038)
- Cancer Bulletins (543)
- Cancer Clinical Trials (5107)
- Cancer Treatment (1240)
- Colon Rectal Cancer (5960)
- General Cancer (17337)
- Leukemia Lymphoma Cancer (10605)
- Lung Mesothelioma Asbestos (4905)
- Ovarian Cervical Uterine Cancer (1176)
- Pancreatic Cancer (56)
- Prostate Cancer (6907)
- Skin Cancer (6052)
- Uncategorized (53)
-
Cancer News Topics
- Breast cancer treatment ‘very effective’
- Chemical that makes naked mole rats cancer-proof discovered
- Estrogen is a new weapon against urinary tract infection in postmenopausal women
- Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma
- Naked mole-rat gives cancer clues
- Researchers Discover Secret To Naked Moles Rats Resistance To Cancer
- How to find the right sunscreen for kids
- TrueBliss Launch Dance Challenge for Child Cancer
- ‘Chase and Run’ Mechanism Explains Cancer Metastasis
- Climb4Life to raise money Saturday in Boulder for ovarian cancer research
- Climb4Life to raise money Saturday in Boulder for ovarian cancer research
- Denver Zoo lion gets unique cancer treatment
- Denver Zoo lion gets unique cancer treatment
- Observation is safe, cost-saving in low-risk prostate cancer
- Observation is safe, cost-saving in low-risk prostate cancer
- Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells
- Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells
- Whole Exome Sequencing Seeks Out Adenoid Cystic Carcinoma
- ‘Undruggable’ To Druggable: A New Target For Cancer Drug Development
- ‘Undruggable’ To Druggable: A New Target For Cancer Drug Development
- Aspirin may fight cancer by slowing DNA damage
- Nanog protein promotes growth of head and neck cancer
- New resistance mechanism to chemotherapy in breast and ovarian cancer
- Chemical probe confirms that body makes its own rotten egg gas, H2S, to benefit health
- Reader Submitted: Terri Brodeur Breast Cancer Foundation Seeks Two Team Lead Volunteers
